Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 8/20 | 0.60 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | TYRO3 | Q06418 | 7/20 | 0.40 |
| ▸ | FLT3 | P36888 | 4/20 | 0.40 |
| ▸ | GAS6 | Q14393 | 4/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16429175 | 1.00 | MERTK (0.60) | MERTKGSK3AGSK3BJAK1TYK2 | |
| SCHEMBL4065318 | 0.87 | KMT2A (0.50) | MERTKJAK1TYK2AXLMEN1 | |
| SCHEMBL29991645 | 0.87 | KMT2A (0.50) | MERTKJAK1TYK2AXLMEN1 | |
| SCHEMBL26930678 | 0.82 | MERTK (0.59) | MERTKTYRO3FLT3GAS6PPARG | |
| SCHEMBL26930671 | 0.82 | MERTK (0.59) | MERTKTYRO3FLT3GAS6PPARG | |
| SCHEMBL31585685 | 0.81 | GSK3A (0.45) | MERTKGSK3AGSK3BJAK1TYK2 | |
| SCHEMBL26931042 | 0.80 | MERTK (0.57) | MERTKTYRO3FLT3GAS6PPARG | |
| SCHEMBL26931049 | 0.80 | MERTK (0.57) | MERTKTYRO3FLT3GAS6PPARG | |
| SCHEMBL23364910 | 0.78 | JAK1 (0.58) | MERTKGSK3AGSK3BJAK1TYK2 | |
| SCHEMBL19763688 | 0.78 | JAK1 (0.58) | MERTKGSK3AGSK3BJAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023235925-A1 | COMPOUNDS WITH MERTK ACTIVITY | MONASH UNIVERSITY (AU) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023235925-A1 | COMPOUNDS WITH MERTK ACTIVITY | MONASH UNIVERSITY (AU) | 2023-12-14 | — | — | WO | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649309-B2 | Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-05-16 | — | — | US | disclosed |
| US-9567326-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-02-14 | — | — | US | disclosed |
| US-9567326-B2 | Pyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-02-14 | — | — | US | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| WO-2015157127-A1 | THERAPUETIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2015-10-15 | — | — | WO | disclosed |
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-20150038481-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038481-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290194-A1 | THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, FLT3, TK1 | MERTK 1/4885GSK3A 1312/4885GSK3B 1202/4885 |
| US-20150038481-A1 | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TYMP, TYMS | MERTK 2234/4885GSK3A 3087/4885GSK3B 2430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.